DOCSLIB.ORG

Disease Mechanisms in Mitochondrial Maintenance Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disease Mechanisms in Mitochondrial Maintenance Disorders Disease Mechanisms in Mitochondrial Maintenance Disorders Kamil Sebastian Sitarz MSc Thesis submitted to Newcastle University in candidature for the Degree of Doctor of Philosophy Institute of Genetic Medicine Faculty of Medical Sciences Newcastle University September 2012 This thesis is dedicated to my beloved wife Agnieszka and our dearest daughters Zuzia and Gabrysia for their constant support and unconditional love. Abstract OPA1 and MFN2 are two critical mitochondrial membrane proteins required for mitochondrial fusion. OPA1 mutations account for approximately 60% of cases of autosomal-dominant optic atrophy (DOA) and up to 20% of mutational carriers develop a more severe multi-systemic neurological phenotype (DOA+) in addition to visual failure. MFN2 mutations result in Charcot-Marie-Tooth disease type 2A (CMT-2A) and in a subgroup of patients, the peripheral neuropathy is complicated by optic atrophy, highlighting a degree of phenotypic overlap with DOA+. POLG1 encodes the catalytic subunit of DNA polymerase gamma (POLG) and POLG1- related diseases are clinically highly heterogeneous, ranging from early-onset Alpers- Huttenlocher syndrome to late-onset isolated chronic progressive external ophthalmoplegia. OPA1, MFN2 and POLG1 mutations all result in disturbed mitochondrial DNA (mtDNA) maintenance, with both quantitative (depletion) and qualitative (point mutations and deletions) mtDNA abnormalities having been identified in patient tissue samples. In this PhD project, the disease mechanisms underpinning these nuclear mitochondrial disorders have been studied further. OPA1 and MFN2 mutations were found to result in significant mtDNA proliferation as a likely compensatory mechanism to impaired mitochondrial oxidative phosphorylation. Using a previously-validated repopulation assay, mtDNA replication in cultured POLG1-mutant fibroblasts was severely depressed following a period of ethidium bromide-induced mtDNA depletion. A similar observation was made with OPA1-mutant fibroblasts, but this effect was not as marked as for POLG1-mutant fibroblasts. Significant reorganisation of the mitochondrial network was also apparent for both groups of mutant fibroblasts. Although neuromyelitis optica (NMO) shares some clinical features with DOA, genetic variations within OPA1 are not associated with the risk of developing NMO. Finally, research into DOA and other mitochondrial optic neuropathies have been severely restricted by the lack of the access to retinal ganglion cells (RGCs), precluding direct studies to be performed on the cell type which is preferentially affected in this group of disorders. To circumvent this limitation, human induced pluripotent stem cell (hiPSC) lines have been generated from patient-derived i fibroblasts harbouring confirmed OPA1 mutations. The future differentiation of these induced pluripotent stem cell lines into RGCs will hopefully provide a powerful and versatile tool for disease modelling and the development of targeted therapeutic strategies. ii Acknowledgements First and foremost, I owe my sincerest gratitude to my supervisors, Prof. Patrick Chinnery and Dr Rita Horvath for providing me with the opportunity to undertake this PhD project. I am grateful for their thought-provoking guidance, inspiration and continued support over the past three years. It was the greatest pleasure to be a part of their group. I would like to address my special thanks to Dr Patrick Yu-Wai-Man, who although not being my official supervisor, has provided me with the inspiring suggestions, continual encouragement and invaluable support throughout the entire course of my PhD. I am grateful for all our constructive discussions and the helpful feedback on the drafts of this thesis. I would like to express my appreciation to all the collaborators I had the pleasure to work with. I owe my gratitude to the members of Prof Majlinda Lako’s Stem Cell Group for their continuous willingness to help. At this point, I would like to thank especially Dr Katarzyna Tilgner, for her excellent assistance with the stem cell culture, her patience, and most importantly, for her friendship. My acknowledgements also extend to Dr David Samuels for offering me support with the statistical analyses, and all the members of the Mitochondrial Diagnostic Service (Newcastle upon Tyne) for providing me with the patient tissue samples. A special mention is also deserved by all my fellow colleagues from the PFC group for making the working environment so friendly. I owe many thanks to Drs Angela Pyle and Gavin Hudson, who have been a great support during my PhD. I would also like to thank Phillippa “Pip” Carling and Gerald “Gerry” Pfeffer, for all these great chats we have had over the much-needed cups of coffee. I would like to extend my deepest gratitude to my parents for all their love, constant understanding and endless support in every situation of my life. Lastly, and most importantly, I would like to express my love and appreciation to my wonderful wife, Agnieszka. You gave me the strength to face all the difficulties and you were always by my side during ups and downs. I am so lucky to have you as my best friend, my soul-mate and my wife. iii Author’s Declaration This thesis is submitted for the degree of Doctor of Philosophy in Newcastle University. The research detailed inside was performed in the Mitochondrial Research Group within Institute of Genetic Medicine under the supervision and guidance of Prof. Patrick Chinnery and Dr Rita Horvath, between September 2009 and August 2012. I hereby declare that none of the material presented in this thesis has been previously submitted by me for a degree or any other qualification at this or any other University. Furthermore, it is my own independent work, unless stated otherwise. This copy has been supplied in the understanding that it is copyright material and that no quotation from the thesis may be made without appropriate acknowledgement. Kamil S. Sitarz iv List of Contents Abstract ......................................................................................................................... i Acknowledgements ...................................................................................................... iii Author’s Declaration .................................................................................................. iv List of Contents ............................................................................................................ v Table of Contents ........................................................................................................ vi List of Figures ............................................................................................................. xi List of Tables ........................................................................................................... xviii List of Publications ................................................................................................... xxi Abbreviations ........................................................................................................... xxii Chapter 1 General Introduction .................................................................................. 1 Chapter 2 Research Aims ......................................................................................... 77 Chapter 3 Materials and Methods ............................................................................. 79 Chapter 4 Disruption of Mitochondrial Fusion and MtDNA Maintenance ........... 103 Chapter 5 Investigations of MFN2-Positive Muscle Biopsy .................................. 117 Chapter 6 Neuromyelitis Optica and Genetic Variations within OPA1 ................. 131 Chapter 7 MtDNA Repopulation Assay and Mitochondrial Network Analysis .... 142 Chapter 8 Generation of hiPSCs from OPA1-Mutant Human Fibroblasts ............. 204 Chapter 9 General Discussion ................................................................................ 244 Appendices .............................................................................................................. 252 Bibliography ........................................................................................................... 279 Publications ............................................................................................................. 311 v Table of Contents Chapter 1 General Introduction ............................................................................... 1 1.1 THE MITOCHONDRION ............................................................................................................... 5 1.1.1 Origin ................................................................................................................................... 5 1.1.2 Structure............................................................................................................................... 5 1.2 RESPIRATORY CHAIN ................................................................................................................. 7 1.2.1 Complex I ............................................................................................................................ 8 1.2.2 Complex II ........................................................................................................................... 9 1.2.3 Complex III .......................................................................................................................... 9 1.2.4 Complex IV ......................................................................................................................
Load more

Recommended publications
  • Initial Experience in the Treatment of Inherited Mitochondrial Disease with EPI-743
    Molecular Genetics and Metabolism 105 (2012) 91–102 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Initial experience in the treatment of inherited mitochondrial disease with EPI-743 Gregory M. Enns a,⁎, Stephen L. Kinsman b, Susan L. Perlman c, Kenneth M. Spicer d, Jose E. Abdenur e, Bruce H. Cohen f, Akiko Amagata g, Adam Barnes g, Viktoria Kheifets g, William D. Shrader g, Martin Thoolen g, Francis Blankenberg h, Guy Miller g,i a Department of Pediatrics, Division of Medical Genetics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA 94305-5208, USA b Division of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA c Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA d Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC 29425, USA e Department of Pediatrics, Division of Metabolic Disorders, CHOC Children's Hospital, Orange County, CA 92868, USA f Department of Neurology, NeuroDevelopmental Science Center, Akron Children's Hospital, Akron, OH 44308, USA g Edison Pharmaceuticals, 350 North Bernardo Avenue, Mountain View, CA 94043, USA h Department of Radiology, Division of Pediatric Radiology, Lucile Packard Children's Hospital, Stanford, CA 94305, USA i Department of Anesthesiology, Critical Care Medicine, Stanford University, Stanford, CA 94305, USA article info abstract Article history: Inherited mitochondrial respiratory chain disorders are progressive, life-threatening conditions for which Received 22 September 2011 there are limited supportive treatment options and no approved drugs. Because of this unmet medical Received in revised form 17 October 2011 need, as well as the implication of mitochondrial dysfunction as a contributor to more common age- Accepted 17 October 2011 related and neurodegenerative disorders, mitochondrial diseases represent an important therapeutic target.
    [Show full text]
  • My Beloved Neutrophil Dr Boxer 2014 Neutropenia Family Conference
    The Beloved Neutrophil: Its Function in Health and Disease Stem Cell Multipotent Progenitor Myeloid Lymphoid CMP IL-3, SCF, GM-CSF CLP Committed Progenitor MEP GMP GM-CSF, IL-3, SCF EPO TPO G-CSF M-CSF IL-5 IL-3 SCF RBC Platelet Neutrophil Monocyte/ Basophil B-cells Macrophage Eosinophil T-Cells Mast cell NK cells Mature Cell Dendritic cells PRODUCTION AND KINETICS OF NEUTROPHILS CELLS % CELLS TIME Bone Marrow: Myeloblast 1 7 - 9 Mitotic Promyelocyte 4 Days Myelocyte 16 Maturation/ Metamyelocyte 22 3 – 7 Storage Band 30 Days Seg 21 Vascular: Peripheral Blood Seg 2 6 – 12 hours 3 Marginating Pool Apoptosis and ? Tissue clearance by 0 – 3 macrophages days PHAGOCYTOSIS 1. Mobilization 2. Chemotaxis 3. Recognition (Opsonization) 4. Ingestion 5. Degranulation 6. Peroxidation 7. Killing and Digestion 8. Net formation Adhesion: β 2 Integrins ▪ Heterodimer of a and b chain ▪ Tight adhesion, migration, ingestion, co- stimulation of other PMN responses LFA-1 Mac-1 (CR3) p150,95 a2b2 a CD11a CD11b CD11c CD11d b CD18 CD18 CD18 CD18 Cells All PMN, Dendritic Mac, mono, leukocytes mono/mac, PMN, T cell LGL Ligands ICAMs ICAM-1 C3bi, ICAM-3, C3bi other other Fibrinogen other GRANULOCYTE CHEMOATTRACTANTS Chemoattractants Source Activators Lipids PAF Neutrophils C5a, LPS, FMLP Endothelium LTB4 Neutrophils FMLP, C5a, LPS Chemokines (a) IL-8 Monocytes, endothelium LPS, IL-1, TNF, IL-3 other cells Gro a, b, g Monocytes, endothelium IL-1, TNF other cells NAP-2 Activated platelets Platelet activation Others FMLP Bacteria C5a Activation of complement Other Important Receptors on PMNs ñ Pattern recognition receptors – Detect microbes - Toll receptor family - Mannose receptor - bGlucan receptor – fungal cell walls ñ Cytokine receptors – enhance PMN function - G-CSF, GM-CSF - TNF Receptor ñ Opsonin receptors – trigger phagocytosis - FcgRI, II, III - Complement receptors – ñ Mac1/CR3 (CD11b/CD18) – C3bi ñ CR-1 – C3b, C4b, C3bi, C1q, Mannose binding protein From JG Hirsch, J Exp Med 116:827, 1962, with permission.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Haematological Abnormalities in Mitochondrial Disorders
    Singapore Med J 2015; 56(7): 412-419 Original Article doi: 10.11622/smedj.2015112 Haematological abnormalities in mitochondrial disorders Josef Finsterer1, MD, PhD, Marlies Frank2, MD INTRODUCTION This study aimed to assess the kind of haematological abnormalities that are present in patients with mitochondrial disorders (MIDs) and the frequency of their occurrence. METHODS The blood cell counts of a cohort of patients with syndromic and non-syndromic MIDs were retrospectively reviewed. MIDs were classified as ‘definite’, ‘probable’ or ‘possible’ according to clinical presentation, instrumental findings, immunohistological findings on muscle biopsy, biochemical abnormalities of the respiratory chain and/or the results of genetic studies. Patients who had medical conditions other than MID that account for the haematological abnormalities were excluded. RESULTS A total of 46 patients (‘definite’ = 5; ‘probable’ = 9; ‘possible’ = 32) had haematological abnormalities attributable to MIDs. The most frequent haematological abnormality in patients with MIDs was anaemia. 27 patients had anaemia as their sole haematological problem. Anaemia was associated with thrombopenia (n = 4), thrombocytosis (n = 2), leucopenia (n = 2), and eosinophilia (n = 1). Anaemia was hypochromic and normocytic in 27 patients, hypochromic and microcytic in six patients, hyperchromic and macrocytic in two patients, and normochromic and microcytic in one patient. Among the 46 patients with a mitochondrial haematological abnormality, 78.3% had anaemia, 13.0% had thrombopenia, 8.7% had leucopenia and 8.7% had eosinophilia, alone or in combination with other haematological abnormalities. CONCLUSION MID should be considered if a patient’s abnormal blood cell counts (particularly those associated with anaemia, thrombopenia, leucopenia or eosinophilia) cannot be explained by established causes.
    [Show full text]
  • Diagnosis of Mitochondrial Diseases: Clinical and Histological Study of Sixty Patients with Ragged Red Fibers
    Original Article Diagnosis of mitochondrial diseases: Clinical and histological study of sixty patients with ragged red fibers Sundaram Challa, Meena A. Kanikannan*, Murthy M. K. Jagarlapudi**, Venkateswar R. Bhoompally***, Mohandas Surath*** Departmetns of Pathology and *Neurology, Nizam’s Institute of Medical Sciences, Hyderabad. **Institute of Neurological Sciences, Care Hospital, ***L.V. Prasad Eye Institute, Hyderabad, India. Background: Mitochondrial diseases are caused by muta- group of patients. tions in mitochondrial or nuclear genes, or both and most Key Words: Mitochondrial disease, Ragged-red fiber, Pro- patients do not present with easily recognizable disorders. gressive external ophthalmoplegia, Kearns-Sayre syndrome, The characteristic morphologic change in muscle biopsy, Myoclonus epilepsy with ragged-red fibers, Heart block. ragged-red fibers (RRFs) provides an important clue to the diagnosis. Materials and Methods: Demographic data, pre- senting symptoms, neurological features, and investigative findings in 60 patients with ragged-red fibers (RRFs) on muscle biopsy, seen between January 1990 and December Introduction 2002, were analyzed. The authors applied the modified res- piratory chain (RC) diagnostic criteria retrospectively to de- Mitochondrial diseases with ragged-red muscle fibers (RRF) termine the number of cases fulfilling the diagnostic criteria as well as some without RRF, are caused by mutations in mi- of mitochondrial disease. Results: The most common clini- tochondrial or nuclear genes, or both, which are normally in- cal syndrome associated with RRFs on muscle biopsy was volved in the formation and maintenance of a functionally in- progressive external ophthalmoplegia (PEO) with or with- tact oxidative phosphorylation system in the mitochondrial out other signs, in 38 (63%) patients. Twenty-six patients inner membrane.1 These disorders present, with bewildering (43%) had only external ophthalmoplegia, 5 (8%) patients array of clinical presentations and are usually dominated by presented with encephalomyopathy.
    [Show full text]
  • Mitochondrial Disease and Endocrine Dysfunction
    Mitochondrial Disease and Endocrine Dysfunction Jasmine Chow1, Joyeeta Rahman2, John C Achermann2, Mehul Dattani2,3, Shamima Rahman2,4,* 1Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong 2Genetics and Genomic Medicine, UCL Institute of Child Health, London WC1N 1EH, UK 3Endocrinology Unit, Great Ormond Street Hospital, London WC1N 3JH, UK 4Metabolic Unit, Great Ormond Street Hospital, London WC1N 3JH, UK * Author for correspondence Address for correspondence: Mitochondrial Research Group Genetics and Genomic Medicine UCL Institute of Child Health 30 Guilford Street London WC1N 1EH UK Tel: +44(0)207 905 2608, Fax: +44(0)207 404 6191 Email: [email protected] 1 Abstract: Mitochondria are critical organelles for endocrine health, housing steroid hormone biosynthesis and providing energy in the form of ATP for hormone production and trafficking. Mitochondrial diseases are multisystem disorders of oxidative phosphorylation that are characterised by enormous clinical, biochemical and genetic heterogeneity. Currently mitochondrial disease has been linked to greater than 200 monogenic defects encoded on two genomes, the nuclear genome and the ancient circular mitochondrial genome located within the mitochondria themselves. Endocrine dysfunction is often observed in genetic mitochondrial disease and reflects decreased intracellular production or extracellular secretion of hormones. Diabetes mellitus is the most frequently described endocrine disturbance in patients with inherited mitochondrial disease, but other endocrine manifestations in these patients may include growth hormone deficiency, hypogonadism, adrenal dysfunction, hypoparathyroidism and thyroid disease. Whilst mitochondrial endocrine dysfunction is frequently in the context of multisystem disease, some mitochondrial disorders are characterised by isolated endocrine involvement, and it is anticipated that further monogenic mitochondrial endocrine diseases will be revealed by genome-wide next generation sequencing approaches.
    [Show full text]
  • 030626 Mitochondrial Respiratory-Chain Diseases
    The new england journal of medicine review article mechanisms of disease Mitochondrial Respiratory-Chain Diseases Salvatore DiMauro, M.D., and Eric A. Schon, Ph.D. From the Departments of Neurology (S.D., ore than a billion years ago, aerobic bacteria colonized E.A.S.) and Genetics and Development primordial eukaryotic cells that lacked the ability to use oxygen metabolical- (E.A.S.), Columbia University College of m Physicians and Surgeons, New York. Ad- ly. A symbiotic relationship developed and became permanent. The bacteria dress reprint requests to Dr. DiMauro at evolved into mitochondria, thus endowing the host cells with aerobic metabolism, a 4-420 College of Physicians and Surgeons, much more efficient way to produce energy than anaerobic glycolysis. Structurally, mito- 630 W. 168th St., New York, NY 10032, or at [email protected]. chondria have four compartments: the outer membrane, the inner membrane, the inter- membrane space, and the matrix (the region inside the inner membrane). They perform N Engl J Med 2003;348:2656-68. numerous tasks, such as pyruvate oxidation, the Krebs cycle, and metabolism of amino Copyright © 2003 Massachusetts Medical Society. acids, fatty acids, and steroids, but the most crucial is probably the generation of energy as adenosine triphosphate (ATP), by means of the electron-transport chain and the ox- idative-phosphorylation system (the “respiratory chain”) (Fig. 1). The respiratory chain, located in the inner mitochondrial membrane, consists of five multimeric protein complexes (Fig. 2B): reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase–ubiquinone oxidoreductase (complex I, approximately 46 sub- units), succinate dehydrogenase–ubiquinone oxidoreductase (complex II, 4 subunits), ubiquinone–cytochrome c oxidoreductase (complex III, 11 subunits), cytochrome c oxi- dase (complex IV, 13 subunits), and ATP synthase (complex V, approximately 16 sub- units).
    [Show full text]
  • Mitochondrial Diseases in North America an Analysis of the NAMDC Registry
    ARTICLE OPEN ACCESS Mitochondrial diseases in North America An analysis of the NAMDC Registry Emanuele Barca, MD, PhD, Yuelin Long, MS, Victoria Cooley, MS, Robert Schoenaker, MD, BS, Correspondence Valentina Emmanuele, MD, PhD, Salvatore DiMauro, MD, Bruce H. Cohen, MD, Amel Karaa, MD, Dr. Hirano [email protected] Georgirene D. Vladutiu, PhD, Richard Haas, MBBChir, Johan L.K. Van Hove, MD, PhD, Fernando Scaglia, MD, Sumit Parikh, MD, Jirair K. Bedoyan, MD, PhD, Susanne D. DeBrosse, MD, Ralitza H. Gavrilova, MD, Russell P. Saneto, DO, PhD, Gregory M. Enns, MBChB, Peter W. Stacpoole, MD, PhD, Jaya Ganesh, MD, Austin Larson, MD, Zarazuela Zolkipli-Cunningham, MD, Marni J. Falk, MD, Amy C. Goldstein, MD, Mark Tarnopolsky, MD, PhD, Andrea Gropman, MD, Kathryn Camp, MS, RD, Danuta Krotoski, PhD, Kristin Engelstad, MS, Xiomara Q. Rosales, MD, Joshua Kriger, MS, Johnston Grier, MS, Richard Buchsbaum, John L.P. Thompson, PhD, and Michio Hirano, MD Neurol Genet 2020;6:e402. doi:10.1212/NXG.0000000000000402 Abstract Objective To describe clinical, biochemical, and genetic features of participants with mitochondrial diseases (MtDs) enrolled in the North American Mitochondrial Disease Consortium (NAMDC) Registry. Methods This cross-sectional, multicenter, retrospective database analysis evaluates the phenotypic and molecular characteristics of participants enrolled in the NAMDC Registry from September 2011 to December 2018. The NAMDC is a network of 17 centers with expertise in MtDs and includes both adult and pediatric specialists. Results One thousand four hundred ten of 1,553 participants had sufficient clinical data for analysis. For this study, we included only participants with molecular genetic diagnoses (n = 666).
    [Show full text]
  • Diagnostic Approach in Infants and Children with Mitochondrial Diseases Ching-Shiang Chi*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Pediatrics and Neonatology (2015) 56,7e18 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.pediatr-neonatol.com INVITED REVIEW ARTICLE Diagnostic Approach in Infants and Children with Mitochondrial Diseases Ching-Shiang Chi* Department of Pediatrics, Tungs’ Taichung Metroharbor Hospital, Taichung, Taiwan Received Mar 17, 2014; accepted Mar 27, 2014 Available online 20 August 2014 Key Words Mitochondrial diseases are a heterogeneous group of disorders affecting energy production in diagnosis; the human body. The diagnosis of mitochondrial diseases represents a challenge to clinicians, infants and children; especially for pediatric cases, which show enormous variation in clinical presentations, as well mitochondrial as biochemical and genetic complexity. diseases; Different consensus diagnostic criteria for mitochondrial diseases in infants and children are Taiwan available. The lack of standardized diagnostic criteria poses difficulties in evaluating diag- nostic methodologies. Even though there are many diagnostic tools, none of them are sensitive enough to make a confirmative diagnosis without being used in combination with other tools. The current approach to diagnosing and classifying mitochondrial diseases incorporates clin- ical, biochemical, neuroradiological findings, and histological criteria, as well as DNA-based molecular diagnostic testing. The confirmation or exclusion of
    [Show full text]
  • View of Cryostat Section; Islet of Stained Cells Sur- Liver:Figure Ultrastructure 8 and Reaction for Cytochrome Oxidase Rounded by Unstained Parenchyma
    BMC Clinical Pathology BioMed Central Research article Open Access Mitochondrial mosaics in the liver of 3 infants with mtDNA defects Frank Roels*1, Patrick Verloo2, François Eyskens3, Baudouin François4, Sara Seneca5, Boel De Paepe2, Jean-Jacques Martin6, Valerie Meersschaut7, Marleen Praet1, Emmanuel Scalais8, Marc Espeel9, Joél Smet2, Gert Van Goethem10 and Rudy Van Coster*2 Address: 1Department of Pathology, Ghent University Hospital, block A, De Pintelaan 185, 9000 Gent, Belgium, 2Department of Pediatrics, Division of Pediatric Neurology, Ghent University Hospital, Ghent, Belgium, 3Metabolic Unit, PCMA, Antwerp, Belgium, 4Centre Pinocchio CHC Clinique de l'Espérance, Montegnée, Belgium, 5Center for Medical Genetics, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium, 6Neuropathology, University of Antwerp, Antwerp, Belgium, 7Radiology and Medical Imaging, Ghent University Hospital, Belgium, 8Division of Paediatric Neurology, Centre hospitalier de Luxembourg, Luxembourg, 9Human Anatomy and Embryology, Ghent University, Ghent, Belgium and 10Division of Neurology and Neuromuscular Reference Center, University Hospital of Antwerp, Antwerp, Belgium Email: Frank Roels* - [email protected]; Patrick Verloo - [email protected]; François Eyskens - [email protected]; Baudouin François - [email protected]; Sara Seneca - [email protected]; Boel De Paepe - [email protected]; Jean- Jacques Martin - [email protected]; Valerie Meersschaut - [email protected]; Marleen Praet - [email protected]; Emmanuel Scalais - [email protected]; Marc Espeel - [email protected]; Joél Smet - [email protected]; Gert Van Goethem - [email protected]; Rudy Van Coster* - [email protected] * Corresponding authors Published: 5 June 2009 Received: 9 July 2008 Accepted: 5 June 2009 BMC Clinical Pathology 2009, 9:4 doi:10.1186/1472-6890-9-4 This article is available from: http://www.biomedcentral.com/1472-6890/9/4 © 2009 Roels et al; licensee BioMed Central Ltd.
    [Show full text]
  • The Phenotypic Spectrum of 47 Czech Patients with Single, Large-Scale Mitochondrial DNA Deletions
    brain sciences Article The Phenotypic Spectrum of 47 Czech Patients with Single, Large-Scale Mitochondrial DNA Deletions Nicole Anteneová 1, Silvie Kelifová 1, Hana Koláˇrová 1, AlžbˇetaVondráˇcková 1, Iveta Tóthová 1, Petra Lišková 1,2, Martin Magner 1,3, Josef Zámeˇcník 4, Hana Hansíková 1, Jiˇrí Zeman 1, 1, , 1, Markéta Tesaˇrová * y and Tomáš Honzík y 1 Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Ke Karlovu 2, 128 08 Prague 2, Czech Republic; [email protected] (N.A.); [email protected] (S.K.); [email protected] (H.K.); [email protected] (A.V.); [email protected] (I.T.); [email protected] (P.L.); [email protected] (M.M.); [email protected] (H.H.); [email protected] (J.Z.); [email protected] (T.H.) 2 Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 128 08 Prague 2, Czech Republic 3 Department of Paediatrics, First Faculty of Medicine, Charles University and Thomayer Hospital, Vídeˇnská 800, 140 59 Prague 4, Czech Republic 4 Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, 150 06 Prague 5, Czech Republic; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 15 September 2020; Accepted: 19 October 2020; Published: 22 October 2020 Abstract: Background: In this retrospective study, we analysed clinical, biochemical and molecular genetic data of 47 Czech patients with Single, Large-Scale Mitochondrial DNA Deletions (SLSMD).
    [Show full text]
  • EFNS Guidelines on the Molecular Diagnosis of Mitochondrial Disorders
    European Journal of Neurology 2009, 16: 1255–1264 doi:10.1111/j.1468-1331.2009.02811.x EFNS GUIDELINES/CME ARTICLE EFNS guidelines on the molecular diagnosis of mitochondrial disorders J. Finsterera, H. F. Harbob, J. Baetsc,d,e, C. Van Broeckhovend,e, S. Di Donatof, B. Fontaineg, P. De Jonghec,d,e, A. Lossosh, T. Lynchi, C. Mariottij, L. Scho¨lsk, A. Spinazzolal, Z. Szolnokim, S. J. Tabrizin, C. M. E. Tallakseno, M. Zevianil, J.-M. Burgunderp and T. Gasserq aKrankenanstalt Rudolfstiftung, Vienna, Danube University Krems, Krems, Austria; bDepartment of Neurology, Ulleva˚l, Oslo University Hospital, and Faculty Division Ulleva˚l, University of Oslo, Oslo, Norway; cDepartment of Neurology, University Hospital Antwerp, Antwerpen; dDepartment of Molecular Genetics, VIB, Antwerpen; eLaboratory of Neurogenetics, Institute Born-Bunge; University of Antwerp, Antwerpen, Belgium; fFondazione-IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy; gAssistance Publique-Hoˆpitaux de Paris, Centre de Re´fe´rence des Canalopathies Musculaires, Groupe Hospitalier Pitie´-Salpeˆtrie`re, Paris, France; hDepartment of Neurology, Hadassah University Hospital, Jerusalem, Israel; iThe Dublin Neurological Institute, Mater Misericordiae University, Beaumont & Mater Private Hospitals, Dublin, Ireland; jUnit of Biochemistry and Genetic of Neurogenetic and Metabolic Diseases, IRCCS Foundation, Neurological Institute Carlo Besta, Milan, Italy; kClinical Neurogenetics, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tu¨bingen, Tu¨bingen,
    [Show full text]